RoyHowardPerlisMD

Director of the Center for Experimental Drugs and Diagnostics (CEDD) and Associate Director of the Psychiatric Genetics Program in Mood and Anxiety Disorders in the MGH Psychiatry Department Associate Professor of Psychiatry at Harvard Medical School and serves as a consultant to the American Psychiatric Association's bipolar treatment guidelines workshop

Join to view full profile

Dr. Perlis is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Perlis' full profile

Already have an account?

Office
15 Parkman Street Wac 812
Psychiatry Outpatient Department
Boston, MA 02114
Phone+1 617-724-5600

Fax+1 617-724-3028

Education & Training

Massachusetts General Hospital/McLean HospitalResidency, Psychiatry, 1997 - 2001
Massachusetts General HospitalInternship, Internal Medicine, 1997 - 1998
Harvard Medical SchoolClass of 1997

Certifications & Licensure

MA State Medical License 1998 - 2026
American Board of Psychiatry and Neurology Psychiatry

Clinical Trials

Effectiveness of Pramipexole for Treatment-Resistant Depression Start of enrollment: 2003 Sep 01
Completed
Phase 4
Simvastatin Augmentation of Lithium Treatment in Bipolar Depression Start of enrollment: 2012 Aug 01
Terminated
Phase 2
Adjunctive Isradipine for the Treatment of Bipolar Depression Start of enrollment: 2013 Feb 01
Terminated
Phase 2

Publications & Presentations

PubMed

Researchers Compared Hospital Early Warning Scores for Clinical Deterioration-Here's What They Learned.
Roy Perlis, Jennifer Abbasi
JAMA. 2025-02-04
Reply to: "Correspondence to bipolar disorder-iPSC derived neural progenitor cells exhibit dysregulation of store-operated Caentry and accelerated differentiation" by ...
Tristen Hewitt, Begüm Alural, Natalina Becke, Steven D Sheridan, Roy H Perlis
Molecular Psychiatry. 2025-02-01
Study Finds People Prefer AI Over Clinician Responses to Questions in the Electronic Medical Record.
Roy Perlis, Nora Collins
JAMA. 2025-01-31

Journal Articles

Psychiatry and COVID-19
Roy Perlis, Donald Goff, JAMA
Can Electronic Health Records Revive Central Nervous System Clinical Trials?
Maurizio Fava, Roy H Perlis, Nature
Temporal Trends and Characteristics of Reportable Health Data Breaches, 2010-2017
Roy Perlis, MD, JAMA

Lectures

Effect of Cytochrome CYP2C19 Metabolizing Activity on Antidepressant Response and Side Effects: Meta-Analysis of Data from Genome-Wide Association Studies
162nd Annual Meeting, San Francisco, California, USA
Discovery of a Highly Selective Glycogen Synthase Kinase‐3 Inhibitor (PF‐04802367) That Modulates Tau Phosphorylation in the Brain: Translation for PET Neuroimaging
American Psychiatric Association, 162nd Annual Meeting, San Francisco, California, USA

Authored Content

The Time Has Come for Over-the-Counter AntidepressantsApril 2024
Genome-Wide Association Study of Dimensional Psychopathology Using Electronic Health RecordsFebruary 2018
High Throughput Phenotyping for Dimensional Psychopathology in Electronic Health RecordsFebruary 2018

Press Mentions

What Happens When AI Is Used to Recommend Treatments for Patients with Bipolar Disorder?September 16th, 2024
Trust in Physicians and Hospitals During the COVID-19 Pandemic in a 50-State Survey of US AdultsAugust 26th, 2024
Benchmarks: Mass General Research News and Notes for August 9, 2024August 9th, 2024
Join now to see all

Grant Support

In Vitro And In Vivo Study Of Simvastatin PLUS Lithium In Bipolar DepressionNational Institute Of Mental Health2012
Building A Risk Stratification Model For Treatment Resistance In Major DepressiveNational Institute Of Mental Health2009–2011
Pramipexole In Treatment-Resistant DepressionNational Institute Of Mental Health2003–2007